We are live on ! Find out more
AIM

AIM ImmunoTech
AIM

33 hedge funds and large institutions have $5.6M invested in AIM ImmunoTech in 2020 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 8 increasing their positions, 8 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

17% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 6

3% more funds holding

Funds holding: 32 → 33 (+1)

0% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 8

5% less capital invested

Capital invested by funds: $5.88M → $5.6M (-$282K)

Holders
33
Holders Change
+1
Holders Change %
+3.13%
% of All Funds
0.58%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
8
Reduced
8
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
+$387K
2
Vanguard Group
Vanguard Group
Pennsylvania
+$335K
3
BCM
Bridgeway Capital Management
Texas
+$222K
4
VF
Virtu Financial
New York
+$149K
5
Verition Fund Management
Verition Fund Management
Connecticut
+$40.2K

Top Sellers

Rank Fund Capital Flow
1
GCP
GSA Capital Partners
United Kingdom
-$157K
2
HighTower Advisors
HighTower Advisors
Illinois
-$151K
3
BCM
Bayesian Capital Management
New York
-$91K
4
Citadel Advisors
Citadel Advisors
Florida
-$36K
5
WS
Wedbush Securities
California
-$29K
Name Holding Trade Value Shares
Change 		Change in
Stake
Morgan Stanley
1
Morgan Stanley
New York
$1.79M +$387K +1,936 +24%
Vanguard Group
2
Vanguard Group
Pennsylvania
$1.02M +$335K +1,673 +41%
BlackRock
3
BlackRock
New York
$914K +$16.2K +81 +2%
Geode Capital Management
4
Geode Capital Management
Massachusetts
$420K +$27K +135 +6%
T. Rowe Price Associates
5
T. Rowe Price Associates
Maryland
$209K – – –
BCM
6
Bridgeway Capital Management
Texas
$199K +$222K +1,111 New
VF
7
Virtu Financial
New York
$186K +$149K +743 +251%
Northern Trust
8
Northern Trust
Illinois
$115K -$1.8K -9 -1%
Verition Fund Management
9
Verition Fund Management
Connecticut
$107K +$40.2K +201 +50%
SWM
10
SeaCrest Wealth Management
New York
$87K -$3.4K -17 -3%
Wells Fargo
11
Wells Fargo
California
$73K -$4.4K -22 -5%
Cambridge Investment Research Advisors
12
Cambridge Investment Research Advisors
Iowa
$73K +$13K +65 +19%
Bank of New York Mellon
13
Bank of New York Mellon
New York
$50K – – –
Charles Schwab
14
Charles Schwab
California
$37K – – –
SFI
15
Susquehanna Fundamental Investments
Pennsylvania
$36K +$17.2K +86 +74%
AWA
16
Arkadios Wealth Advisors
Georgia
$35K – – –
Rockefeller Capital Management
17
Rockefeller Capital Management
New York
$35K – – –
GCP
18
GSA Capital Partners
United Kingdom
$31K -$157K -787 -82%
Bank of America
19
Bank of America
North Carolina
$27K -$3.4K -17 -10%
TCM
20
Traynor Capital Management
Pennsylvania
$26K – – –
LPL Financial
21
LPL Financial
California
$22K -$16K -80 -39%
TRCT
22
Tower Research Capital (TRC)
New York
$22K +$25K +125 New
XM
23
XTX Markets
New York
$20K -$1.8K -9 -8%
HF
24
HRT Financial
New York
$20K +$23.4K +117 New
AWM
25
Act Wealth Management
Texas
$18K +$20K +100 New
1
2

AIM Hedge Fund Activity: Q4 2020 in Review

33 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in AIM ImmunoTech (AIM) for Q4 2020, worth a combined $5.6M — down 4.8% from $5.88M a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new AIM positions and 6 closed out — a net gain of 1 holder — while 8 added to existing stakes and 8 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $387K. The largest seller was GSA Capital Partners, cutting an estimated $157K.

  • 33 institutional investors held AIM ImmunoTech (AIM) as of Q4 2020, up from 32 in Q3 2020.
  • Funds reported $5.6M of AIM ImmunoTech stock for Q4 2020, down 4.8% quarter-over-quarter.
  • 7 funds opened new AIM ImmunoTech positions in Q4 2020 and 6 closed out, a net change of +1 holder.
  • The largest AIM ImmunoTech buyer in Q4 2020 was Morgan Stanley, an estimated $387K added.
  • The largest AIM ImmunoTech seller in Q4 2020 was GSA Capital Partners, an estimated $157K sold.

Based on aggregated 13F filings for Q4 2020.